Quick Facts: Main Uses

• Gastric Ulcers: May assist in the healing process of gastric ulcers.
• Gastritis: Helps address lesions of the gastric lining (erosion, bleeding, redness, and swelling) in cases of acute gastritis and flare-ups of chronic gastritis.
• NSAID-Induced Injury: Supports the protection of the gastrointestinal lining against damage that may result from the use of nonsteroidal anti-inflammatory drugs (NSAIDs).

---

Ребамипид is an agent used to support the lining of the gastrointestinal tract and is prescribed to help manage several conditions affecting the stomach and intestines. Clinical use generally centers on the therapeutic domain of mucosal protection and wound healing within the upper gastrointestinal tract.

The medication may contribute to the healing of established gastric ulcers. It is also indicated for managing gastric mucosal lesions—including erosion, bleeding, redness, and swelling—associated with acute gastritis and periods of acute worsening in chronic gastritis. This drug is utilized to support the integrity of the gastric and intestinal lining, particularly as a measure against injury that may occur following the use of certain nonsteroidal anti-inflammatory drugs (NSAIDs). The therapeutic role involves processes that help enhance the body's natural defense mechanisms in the stomach.

Contraindicated and Restricted Populations

The use of Rebamipide is strictly contraindicated for certain populations as defined by regulatory documents. Patients with a known history of hypersensitivity to Rebamipide or any of its components must not use the medicine. It is also contraindicated for nursing mothers, with official labeling advising that nursing must be interrupted if the medicine is administered.

---

Age and Condition Eligibility

Standard use is established for adults. Use in pediatric patients is not recommended because safety and efficacy have not been established due to insufficient clinical data. Older adults should use the medicine with special care due to potential physiological sensitivity.

---

Conditional Use and Caution

For pregnant or possibly pregnant women, safety has not been established, and use is only permitted if the anticipated therapeutic benefit is deemed to outweigh any potential risk. Caution is required for patients with renal impairment because of the potential for altered drug concentrations and prolonged half-life. Caution is also advised regarding hepatic dysfunction, as official documentation notes that increases in liver enzymes may necessitate discontinuation.

Interactions with other medicines and products

The official regulatory profile for Rebamipide is characterized by a generally low risk of clinically significant drug-drug interactions. The available prescribing information does not list specific co-administered medicinal products that are formally contraindicated or require mandatory timing separation.

Documented Interaction Patterns

The most specific interaction information relates to pharmacokinetic modification tied to the patient’s physiological condition, rather than co-administered substances. The following patterns are documented in regulatory labeling:

---

• Medicinal Products: No specific interacting medicines are explicitly listed in official drug interaction sections.
• Food/Substances: No mandatory restrictions or formal warnings are documented regarding co-administration with food, alcohol, or herbal products.
• Timing Rules: No requirements for separating the administration time of Rebamipide from other drugs are specified in the official documents.

---

Population-Specific Exposure Modification

The primary documented interaction involves exposure alteration in a specific patient group:

Condition
Renal Impairment

In patients with renal impairment (compromised kidney function), the pharmacokinetics of Rebamipide are altered. Official data indicates that higher plasma concentrations and a longer elimination half-life are observed in this population compared to healthy individuals, formally documenting a population-dependent exposure modification. However, studies following repeated administration in dialyzed renal patients suggest that the drug is not expected to accumulate at steady-state. This defines the core constraint within the drug's official interaction profile.

Ребамипид exerts its action on the mucosal layer primarily through stimulating endogenous prostaglandin E2 production within the gastric mucosa . This stimulation contributes to the maintenance of the gastrointestinal lining integrity by influencing the mucus layer and regulating epithelial tight junctions. This process also modulates inflammatory signaling pathways.

---

Inhibition of Bacterial Adhesion

The compound also inhibits the adherence of Helicobacter pylori to the gastric epithelial cells. This physical interference with colonization is a key component of its multi-modal action against potential gastric stressors.

---

Vascular and Tissue Regeneration Effects

Furthermore, Rebamipide modulates blood flow to the mucosal layer. The resulting change in local circulation influences the tissue regeneration process following physiological perturbation. This multi-modal action profile reflects the influence on multiple biological targets within the gastric environment.

The administration of Rebamipide is based on standardized clinical protocols for its use as an oral medication. The active ingredient is formulated as a 100 mg film-coated tablet, which is the primary unit strength for treatment. The standard adult dosing regimen for gastrointestinal uses involves taking one 100 mg tablet three times daily, resulting in a total daily dose of 300 mg.

Dosing and Administration Specifics

The drug is administered via the oral route. The frequency is typically set at three times daily for primary indications, including both gastric ulcers and the improvement of gastric mucosal lesions associated with gastritis. For the management of gastric ulcers, the doses are generally spaced throughout the day: in the morning, in the evening, and once at bedtime. Administration is flexible regarding meals, as the drug may be taken with or without food because bioavailability is not significantly affected by co-administration with a meal.

Dose Management and Special Populations

To maintain the required daily dosage, a specific protocol applies to missed doses: if a scheduled dose is forgotten, it should be taken as soon as possible, but if it is almost time for the next dose, the missed one must be skipped entirely, and two doses should never be taken at one time. For special populations, patients with renal impairment may exhibit higher plasma concentrations and a longer elimination half-life; therefore, close monitoring is generally warranted. Use in older adults also requires caution and attention to proper administration.

Research Evidence / Overview of Studies

This section reviews studies that examined the activity of Rebamipide in relation to symptoms associated with various gastrointestinal conditions, including gastric ulcers and gastritis. Overall, studies have investigated the potential of Rebamipide to influence the severity and frequency of various symptoms of these conditions.

---

Clinical Efficacy and Outcomes

A range of randomized controlled trials (RCTs) have been conducted. These studies compared Rebamipide to a placebo or other active treatments over specified periods.

• Ulcer Healing: A key finding was the difference in endoscopic healing rates between the active treatment group and control groups. The largest RCT, involving a substantial number of participants, reported differences in healing rates favoring the Rebamipide group.
• Symptom Relief: Studies also evaluated the frequency and severity of symptoms such as abdominal pain and discomfort. Some research found a potential association between Rebamipide use and a reduced frequency and severity of reported symptoms.
• Secondary Effects: Secondary findings include reports of changes in mucosal inflammation and investigations into potential changes in protective prostaglandin levels.

---

Comparisons to Other Treatments

Studies have explored the relative outcomes when Rebamipide is compared to other established therapies.

• vs. PPIs (Proton Pump Inhibitors): Trials often evaluated Rebamipide as an add-on therapy. The findings suggest a potential difference in outcomes when used in combination with PPIs, though the difference was not consistently reported across all metrics when used as monotherapy versus PPIs.

---

Safety Profile and Special Populations

Long-term evidence has evaluated the safety profile.

• Adverse Events: The most commonly reported adverse events in clinical trials included mild gastrointestinal issues and hypersensitivity reactions. These were generally described as mild and transient.
• Pregnancy and Planning: Research evaluating the use of Rebamipide in women who are pregnant or planning to be remains limited.

Key Studies & References Rebamipide Tablets 100mg Otsuka Product Information (Indications and Dosage, Japan Regulatory Document).

Common questions about Ребамипид (FAQ)

Q: Does Ребамипид interact with alcohol?

Official documents do not list a formal pharmacokinetic or pharmacodynamic interaction between this medicine and alcohol. However, caution is tied to the fact that alcohol consumption can increase the production of stomach acid. Since the medicine is used to treat conditions exacerbated by stomach acid, this information is provided to help understand the associated physiological risks.

Q: Does Ребамипид interact with common pain relievers?

The official regulatory profile indicates a generally low risk of clinically significant drug-drug interactions. Because of this, specific common pain relievers are typically not listed as being formally contraindicated in the drug interaction sections of the product information.

Q: Can a person take Ребамипид if they are taking medicine for high blood pressure?

The official regulatory documents for this medicine do not list specific medications used for high blood pressure (antihypertensives) as having a formal interaction. The overall risk for clinically significant drug-drug interactions is considered low, according to official information.

Q: Can Ребамипид be taken with medications for diabetes?

Official prescribing information is characterized by a general lack of listed interactions with common medications. Regulatory documents do not specifically list diabetes medications as contraindicated or requiring dosage adjustments when taken with this drug.

Q: Why is this drug sometimes called Rebamipide?

Rebamipide is the internationally recognized name for the active ingredient, established by global regulatory bodies. It is the International Nonproprietary Name (INN) and is used in scientific literature and by drug agencies worldwide. The name Ребамипид is the direct transliteration of the active ingredient name used in certain non-English-speaking regions.

Q: Why is Ребамипид sometimes prescribed for eye issues?

While the oral tablet is primarily used for gastrointestinal conditions, the same active compound is formulated into an ophthalmic (eye drop) solution. This eye drop formulation is separately approved by regulatory bodies in some markets for the specific treatment of dry eye symptoms.

Q: How quickly can a person expect to notice anything after taking Ребамипид?

Official pharmacokinetic studies provide information on how the body handles the medicine. These studies show that the maximum concentration of the drug in the blood plasma (Tmax) is generally reached in approximately 2 to 2.5 hours after an oral dose. This is a measure of absorption, not the immediate onset of clinical relief or feeling better.

Q: Are there generic versions of Ребамипид available?

Yes, the compound Rebamipide is the generic name for the active ingredient. Various generic and branded versions of the medicine, often under different trade names, are marketed and approved by regulatory authorities in different countries where the drug is available.

Q: Does Ребамипид affect appetite?

Adverse reactions documented in official sources include 'loss of appetite' or 'appetite changes' among the reported side effects. These reactions are generally reported as uncommon or mild in the safety documentation.

Q: What type of research has been done on Ребамипид's effect on the stomach?

Research into the medicine’s activity includes several types of studies, as described in regulatory overviews. This includes in vitro laboratory studies, animal models examining ulcer development, and human research such as randomized controlled trials (RCTs). These studies investigated the medicine's role in ulcer healing, symptom reduction, and mucosal protection.

Q: Does Ребамипид have a warning about driving or operating machinery?

Official warnings state that the medicine may cause temporary effects such as dizziness, drowsiness, or blurred vision in some individuals. Due to this potential, the product information contains a caution regarding operating machinery or driving if these temporary effects occur.

Q: What are the main differences between Ребамипид and H2 blockers?

The primary difference is the mechanism of action. H2 blockers primarily function to reduce or block the production of stomach acid. In contrast, this medicine is classified as a mucoprotective agent, meaning its main action is to strengthen and reinforce the stomach's natural protective lining.

Q: Why would a doctor choose Ребамипид over another gastric medication?

The choice of medication is a clinical decision, but regulatory documentation highlights the drug's unique mechanism of action. The drug is described as one that enhances the stomach's natural defense factors, such as stimulating prostaglandin production and inhibiting bacterial adherence, which is an action distinct from simple acid-suppression.

Q: Does Ребамипид have any effects on the intestines, or just the stomach?

The approved indications in regulatory documents include treatment for ulcers in both the stomach (gastric) and the first part of the small intestine (duodenal). Research has focused on its protective effect on the general gastroduodenal mucosa.

Q: Does the efficacy of Ребамипид diminish over time?

Official clinical follow-up studies have examined patients after their ulcers were healed with this treatment. The findings of these studies have reported low rates of ulcer recurrence (relapse) over several months in patients who achieved healing after treatment.

Q: Are there specific food types to avoid while using Ребамипид?

The official prescribing information does not list any mandatory restrictions or formal warnings regarding co-administration with food or specific food types. The medication can generally be taken with or without food.

Q: Is there evidence that Ребамипид helps prevent future ulcers?

Research evidence cited in official documents has investigated the drug's role in ulcer recurrence. Some studies indicate a potential to influence the rate of recurrence of gastric ulcers in certain patient populations after initial healing.

Q: How long does the effect of Ребамипид last after the last dose?

Pharmacokinetic studies detail the elimination half-life (T1/2), which is the time it takes for half the drug to be cleared from the bloodstream. For this medicine, the half-life is reported to be approximately 1.94 hours. This measure relates to drug clearance and does not directly define the duration of the full clinical protective effect on the mucosa.

Q: Is there a risk of dependency with Ребамипид?

Based on official safety data and warnings, regulatory documents do not report any habit-forming tendencies or risk of dependency associated with the use of this medication.

Rebamipide tablets must be stored according to regulatory requirements to ensure product stability. The required storage environment is a cool and dry place, with temperatures generally mandated to be below 30 C. Official labeling explicitly requires that the tablets must be protected from direct sunlight, excessive heat, and moisture.

For safety, the medication must be stored out of the reach of children. Any remainder of a tablet or product that is no longer needed should be discarded and not stored. When disposing of unused or expired medicine, it must be handled responsibly: it should not enter drains, water courses, or the soil, and disposal should follow local regulations via an approved waste disposal plant.